Cargando…
Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial
BACKGROUND: The clinical characteristics and treatment of patients who tested positive for COVID-19 after recovery remained elusive. Effective antiviral therapy is important for tackling these patients. We assessed the efficacy and safety of favipiravir for treating these patients. METHODS: This is...
Autores principales: | Zhao, Hong, Zhang, Chi, Zhu, Qi, Chen, Xianxiang, Chen, Guilin, Sun, Wenjin, Xiao, Zuohan, Du, Weijun, Yao, Jing, Li, Guojun, Ji, Yanhua, Li, Niuniu, Jiang, Yujin, Wang, Ying, Zeng, Qingjin, Li, Wei, Gong, Beilei, Chang, Xianyou, Zhu, Feng, Jiang, Xiufeng, Li, Jiawen, Wu, Zhao, Liu, Yingxia, Peng, Peng, Wang, Guiqiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059985/ https://www.ncbi.nlm.nih.gov/pubmed/33930706 http://dx.doi.org/10.1016/j.intimp.2021.107702 |
Ejemplares similares
-
Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
por: Zhao, Hong, et al.
Publicado: (2021) -
The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial
por: Li, Jiawen, et al.
Publicado: (2020) -
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study()
por: Cai, Qingxian, et al.
Publicado: (2020) -
Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir
por: Peng, Qi, et al.
Publicado: (2021) -
MineProt: a stand-alone server for structural proteome curation
por: Zhu, Yunchi, et al.
Publicado: (2023)